Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | The CLL12 trial of ibrutinib in early stage CLL

Here, Petra Langerbeins, MD, of the University of Cologne, Cologne, Germany, discusses the key outcomes from the CLL12 study (NCT02863718) looking at the use of ibrutinib in early-stage chronic lymphocytic leukemia (CLL). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.